OBJECTIVES:  To estimate the budget impact of Secukinumab in the management of psoriatic arthritis (PsA) in Greece. METHODS: A budget impact model was developed to compare the cost of managing PsA under two scenarios: a treatment mix of currently approved therapies with and without Secukinumab. Population data were taken from OECD population statistics 2015 and were projected with the mean annual growth rate of the time series 2000-2012. Epidemiology data (prevalence and incidence) were taken from Greek published studies. Market shares were based on current patient numbers by treatment regimen retrieved from the University of Peloponnese for the period June 2014 to June 2015. Data on resource use were obtained from the international literature and were validated by Greek clinical experts. Unit costs were taken from officially published Greek sources (Ministry of Health, Social Insurance Funds -SIFs). Only direct costs were considered in the analysis. The time horizon of the analysis was five years and the Social Insurance Fund (EOPYY) perspective was adopted. RESULTS:  In 2016, the total budget of managing psoriatic arthritis in Greece is expected to reach €24 million in the scenario without Secukinumab and €23.2 in the scenario with it, leading to a reduction of 4.1 % of Social Insurance Fund’s (EOPYY’s) budget dedicated to psoriatic arthritis. Total savings of €865,114 are expected to occur in 2016, rising up to €2.7 million in 2020. Over a 5-year time horizon, Secukinumab can lead to cumulative savings of €9.8 million. For naïve patients there are greater savings for EOPPY due to lower dosage scheme. CONCLUSIONS:  Inclusion of Secukinumab in the treatment of psoriatic arthritis in Greece is expected to bring major cost savings to the Social Insurance Fund ranging from €865,114 in 2016 up to 9.8 million in 2020. Greater savings are achieved in the naïve patients’ subgroup.